Invention Application
WO0218540A3 PYRIDINE DERIVATIVES USEFUL AS CD40:CD154 BINDING INTERRUPTOR COMPOUNDS AND USE THEREOF TO TREAT IMMUNOLOGICAL COMPLICATIONS
审中-公开
吡啶衍生物有用的CD40：CD154结合中间体化合物及其用于治疗免疫综合征
- Patent Title: PYRIDINE DERIVATIVES USEFUL AS CD40:CD154 BINDING INTERRUPTOR COMPOUNDS AND USE THEREOF TO TREAT IMMUNOLOGICAL COMPLICATIONS
- Patent Title (中): 吡啶衍生物有用的CD40：CD154结合中间体化合物及其用于治疗免疫综合征
-
Application No.: PCT/US0127361Application Date: 2001-08-31
-
Publication No.: WO0218540A3Publication Date: 2003-12-24
- Inventor: ZHENG ZHONGLI , CARTER MARY-BETH , LIAO YUSHENG , SUN LIHONG , KIRKOVSKY LEONID , MROSE SUSAN , HSU YEN-MING , THOMAS DAVID , SHIPPS GERALD W JR , JINDAL SATISH , LENZ GEORGE R , NASH HUW M
- Applicant: BIOGEN INC , ZHENG ZHONGLI , CARTER MARY-BETH , LIAO YUSHENG , SUN LIHONG , KIRKOVSKY LEONID , MROSE SUSAN , HSU YEN-MING , DAVID THOMAS , SHIPPS GERALD W JR , JINDAL SATISH , LENZ GEORGE R , NASH HUW M
- Assignee: BIOGEN INC,ZHENG ZHONGLI,CARTER MARY-BETH,LIAO YUSHENG,SUN LIHONG,KIRKOVSKY LEONID,MROSE SUSAN,HSU YEN-MING,DAVID THOMAS,SHIPPS GERALD W JR,JINDAL SATISH,LENZ GEORGE R,NASH HUW M
- Current Assignee: BIOGEN INC,ZHENG ZHONGLI,CARTER MARY-BETH,LIAO YUSHENG,SUN LIHONG,KIRKOVSKY LEONID,MROSE SUSAN,HSU YEN-MING,DAVID THOMAS,SHIPPS GERALD W JR,JINDAL SATISH,LENZ GEORGE R,NASH HUW M
- Priority: US23005500 2000-09-01
- Main IPC: F25B9/00
- IPC: F25B9/00 ; A61K31/444 ; A61P1/04 ; A61P1/16 ; A61P9/02 ; A61P9/04 ; A61P9/10 ; A61P11/00 ; A61P11/06 ; A61P13/12 ; A61P17/06 ; A61P19/02 ; A61P25/28 ; A61P27/02 ; A61P29/00 ; A61P35/02 ; A61P37/00 ; A61P37/06 ; A61P37/08 ; C07C311/47 ; C07D401/14 ; F25B9/14
Abstract:
The present invention relates to novel CD40:CD154 binding interruptor compounds of the formula (I), and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
Information query
